Good afternoon All...3 Jun 2019 15:47
The Clinical Study of VAL-201 must finish in June and the data collection submitted to MHRA.Obtaining the necessary financing by whatever means is crucial as it is also a requirement by MHRA for further extension of testing 16mg dose of the drug.If as it seems ,the money will be found,the share price will dramatically shift upwards,since the financier lending money would have been shown the results of the current phase before agreeing to cough up the requested sum.Many people here are forgetting that VAL-201 already had undergone a rigorous testing in the clinical setting(almost 3 years) and without problems.This is far more valuable than a short,with limited number of patients(7) clinical trial in Georgia of VAL-401.Not many lenders would part with their money on the strength of statistics derived there.I feel that in spite of all troubles we have had with Valirx,we are at a point of great rewards with VAL-201.Stach